Seattle Genetics (SGEN) has risen sharply, recording gains of 20.61% in the past 4 weeks. However, the stock has corrected -3.26% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 21.26% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 3.03% and the 50-Day Moving Average is 10.78%.The 200 Day SMA reached 35.34%
Seattle Genetics (NASDAQ:SGEN): After opening at $53.47, the stock dipped to an intraday low of $52.13 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $54.27 and the buying power remained strong till the end. The stock closed at $54.01 for the day, a gain of 1.35% for the day session. The total traded volume was 786,242. The stocks close on the previous trading day was $54.01.
Seattle Genetics (SGEN) : The highest short term price target forecast on Seattle Genetics (SGEN) is $130 and the lowest target price is $38. A total of 10 equity analysts are currently covering the company. The average price of all the analysts is $58.4 with a standard deviation of $26.94.
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.